05.20.25 -- Find Your Ideal CDMO Partner — Fast

In this presentation, we will highlight how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.

Sr. Director of Commercial Operations, Tara Lorenz, speaks on our latest investments and expanded fill/finish capabilities and capacity for small molecules, biologics, and other sterile injectable products.

With expertise in process optimization, analytics, and regulatory strategy, we help partners de-risk development, accelerate time to market, and ensure manufacturability from the outset.

Backed by years of dedication to customer-focused solutions, we’re proud to introduce our specialists to the global biopharma community and share insights that drive innovation forward.

Evan Pasenello, Head of Commercial Services, gives viewers an update on how we can support manufacturing programs from clinical through commercial.

Discover how proven sterile fill-finish expertise, high-potency capabilities, and customizable cleanrooms can support your product from development to commercialization.

Sr. Key Account Manager, Dr. Jürgen Lübbehusen, highlights our overall fill-finish capabilities and capacities, with a focus on our ability to help meet your complex needs.

Executive Director of Technology and Business Development for Drug Product and Finished Goods, Henrik Herrmann, shares an update on the current and future state of FDB’s capabilities.

Advance your clinical and commercial programs with expert aseptic fill finish and formulation services across vials, cartridges, and syringes, all in state-of-the-art, EU Annex 1-compliant facilities.

Associate Director kojoX and Technology Development, Rasmus Petersen, presents a high-level overview of FDB’s capabilities, its global facilities network, and capacity updates for BIOLOGICS.

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

Vice President of Business Development, Detra Glinatsis, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

See first-hand how AbZelectPRO™, an evolved approach to cell line development, can simplify selection, enhance stability, and de-risk your program for faster regulatory approval.

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.

Experience a global network of expertise and proven manufacturing capabilities that can help accelerate your clinical and commercial drug substance programs.

Leveraging advanced technology, expertise, and flexible capacity, clients can reduce development time and costs while ensuring a smooth transition from clinical to commercial manufacturing.

Explore how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.

Uncover how Integrated Unprocessed Bulk testing — including viral assays, NGS, and TEM — can safeguard product safety, minimize contamination risks, and streamline biologics development.

Accelerate your drug development and ensure regulatory compliance with our innovative analytical solutions and advanced nitrosamine testing strategies.

Get the quality, compliance, and accelerated development support you need for your small molecule and cell and gene therapy program with our advanced analytical testing services.

Consider how our end-to-end ADC solutions — from advanced conjugation technologies to scalable manufacturing — can accelerate your therapeutic development.

Our integrated expertise can help you develop and manufacture dual payload ADCs with optimized efficacy, precision conjugation, and scalable solutions.

Witness how proven expertise and expanding capabilities in ADC manufacturing can help you scale high-value injectable therapies with speed, quality, and regulatory confidence.

This presentation offers a global overview of our comprehensive ADC program, providing developers with full end-to-end support — all under a single, streamlined contract.